President Donald Trump announced a historic price reduction for Ozempic, the widely used semaglutide drug for diabetes and weight management, lowering the monthly cost from $1,000 to $199. The price cut is being implemented through the federal TrumpRx.gov platform, which provides printable coupons and facilitates direct access to discounted medications for all Americans, regardless of insurance coverage.

Ozempic has long been criticized for its high cost, driving patients to seek cheaper alternatives abroad. The Trump administration’s initiative aims to improve accessibility and affordability while reducing the financial burden on households. By leveraging bulk government purchasing and international price benchmarking, TrumpRx.gov enforces lower pricing, potentially saving patients billions of dollars annually, similar to prior federal measures that capped insulin at $35 and EpiPens at $250 per month.

Officials stated that the Ozempic discount represents a continuation of the administration’s broader strategy to make essential medications more affordable. Patients can visit TrumpRx.gov, select the medication, and print a coupon for use at participating pharmacies nationwide. The initiative is intended to ensure that Americans do not have to delay or ration critical medications due to cost.

President Trump framed the announcement as a victory for everyday Americans, emphasizing that the federal platform makes it simple, transparent, and equitable for all citizens to access lifesaving drugs. The price reduction underscores the administration’s commitment to using federal resources and negotiation power to confront rising healthcare costs while expanding patient access to necessary treatments.